Protagenic Therapeutics (NASDAQ:PTIX) reported quarterly losses of $(0.11) per share. This is a 83.33 percent decrease over losses of $(0.06) per share from the same period last year.
Scopus BioPharma Names Alan Horsager President Of Co
Scopus BioPharma Inc. (Nasdaq: "SCPS"), a clinical-stage biopharmaceutical company developing transformational therapeutics for serious diseases with significant unmet medical needs, today announced a new